![]() | |
Clinical data | |
---|---|
Other names | GS-9669 |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C30H41NO6S |
Molar mass | 543.72 g·mol−1 |
3D model ( JSmol) | |
| |
|
Radalbuvir ( INN, [1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials. [2] It targets NS5B polymerase. [3]
![]() | |
Clinical data | |
---|---|
Other names | GS-9669 |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C30H41NO6S |
Molar mass | 543.72 g·mol−1 |
3D model ( JSmol) | |
| |
|
Radalbuvir ( INN, [1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials. [2] It targets NS5B polymerase. [3]